The American Journal of Medicine
Volume 123, Issue 7, Supplement , Pages S2-S8 , July 2010

The Role of Nitric Oxide in Improving Endothelial Function and Cardiovascular Health: Focus on Nebivolol

  • George L. Bakris, MD

      Affiliations

    • Hypertensive Diseases Unit, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    • ,
  • Jan N. Basile, MD

      Affiliations

    • Seinsheimer Cardiovascular Health Program, College of Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA
    • ,
  • Thomas D. Giles, MD

      Affiliations

    • Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Thomas D. Giles, MD, 109 Holly Drive, Metairie, Louisiana 70005
    • ,
  • Addison A. Taylor, MD, PhD

      Affiliations

    • Departments of Medicine, Pharmacology, and Molecular Physiology, Baylor College of Medicine, Houston, Texas, USA

References 

  1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  2. Weber MA. The role of the new β-blockers in treating cardiovascular disease. Am J Hypertens. 2005;18(pt 2):169S–176S
  3. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8:840–849
  4. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118–123
  5. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9:269–277
  6. Mason PR, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol. 2006;48:862–869
  7. Stewart FM, Freeman DJ, Ramsay JE, Greer IA, Caslake M, Ferrell WR. Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function through pregnancy in lean and obese mothers. J Clin Endocrinol Metab. 2007;92:969–975
  8. Arkin JM, Alsdorf R, Bigornia S, et al. Relation of cumulative weight burden to vascular endothelial dysfunction in obesity. Am J Cardiol. 2008;101:98–101
  9. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?. Am J Cardiol. 2005;96:13M–18M
  10. Ross R. Atherosclerosis: an inflammatory disease [editorial]. N Engl J Med. 1999;340:115–126
  11. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes (Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)). Circulation. 2006;114:2850–2870
  12. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(pt 2):3S–10S
  13. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the Atherosclerosis Risk in Communities Study. Diabetes. 2002;51:3069–3076
  14. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelial-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 1993;21:1145–1151
  15. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol. 1992;20(suppl 12):S193–S195
  16. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 1993;87:1475–1481
  17. Brett SE, Cockcroft JR, Mant TG, Ritter JM, Chowienczyk PJ. Haemodynamic effects of inhibition of nitric oxide synthase and of l-arginine at rest and during exercise. J Hypertens. 1998;16:429–435
  18. Dhakam Z, Yasmin , McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351–356
  19. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558–569
  20. Berecek KH, Carey RM. Adrenergic and dopaminergic receptors and actions. In:  Izzo JL,  Black HR editor. Hypertension Primer. 3rd ed.. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 1–4
  21. Bristow MR, Nelson P, Minobe W, Johnson C. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens. 2005;18(suppl 4s):51A–52APoster P-121
  22. Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988;11:552–563
  23. Brixius K, Bundkirchen A, Bölck B, Mehlhorn U, Schwinger RH. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001;133:1330–1338
  24. Frishman WH. β1-adrenoceptor selectivity is maintained with increasing doses of the vasodilatory β-blocker nebivolol. J Clin Hypertens (Greenwich). 2008;10(suppl A):A21
  25. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38(suppl 3):S13–S16
  26. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199–204
  27. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511–514
  28. Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J Am Coll Cardiol. 2002;40:754–760
  29. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795–3801
  30. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344–348
  31. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  32. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906
  33. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators, the Anglo-Scandinavian Cardiac Outcomes Trial Investigators, and the CAFE Steering Committee and Writing Committee Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–1225
  34. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? (A meta-analysis). Lancet. 2005;366:1545–1553
  35. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866–875
  36. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591–596
  37. Boydak B, Nalbantgil S, Fici F, et al. A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Invest. 2005;25:409–416
  38. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34:327–331
  39. Flather MD, Shibata MC, Coats AJS, et al. SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225
  40. Basile J. One size does not fit all: the role of vasodilating β-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. Am J Med. 2010;123(suppl):S9–S15
  41. Giles TD. The role of vasodilating β-blockers in patients with complicated hypertension: focus on nebivolol. Am J Med. 2010;xx:xxx-xxx [this issue]
  42. Taylor AA, Bakris GL. The role of vasodilating β-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010;123(suppl):S21–S26

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(10)00338-4

doi: 10.1016/j.amjmed.2010.04.012

The American Journal of Medicine
Volume 123, Issue 7, Supplement , Pages S2-S8 , July 2010

Article Tools

* Image Usage & Resolution